Dr. John H. Scott, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 708
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Virginia Commonwealth University, School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
IA license MD-51776 · PA license MD464250 -
Sleep Medicine (Internal Medicine) Physician
IA license MD-51776
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Mercyone Des Moines Medical Center Des Moines, IA
- Unitypoint Health - Des Moines Iowa Methodist Medi Des Moines, IA
- Pella Regional Health Center Pella, IA
Medical groups
- The Iowa Clinic PC (310 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 708
- Services billed
- 2,174
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 78 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 43 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 32 | 21 |
| Electronic analysis of neurostimulator generator with simple cranial nerve stimulator programming | 23 | 16 |
| Test to measure expiratory airflow and volume | 23 | 23 |
| Test to examine how well the lungs exchange gases | 21 | 21 |
| New patient office or other outpatient visit, 45-59 minutes | 20 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 19 |
| Test to determine lung volumes using gas dilution or washout | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in West Des Moines, IA | 140 |
| Prednisone Other prescribers in West Des Moines, IA | 122 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in West Des Moines, IA | 78 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in West Des Moines, IA | 75 |
| Gabapentin Other prescribers in West Des Moines, IA | 29 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in West Des Moines, IA | 26 |
| Zolpidem Tartrate Other prescribers in West Des Moines, IA | 25 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in West Des Moines, IA | 23 |
| Bumetanide Other prescribers in West Des Moines, IA | 23 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in West Des Moines, IA | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $200 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $150 |
|---|---|
| Inspire Medical Systems, Inc. | $37.09 |
| Itamar Medical Inc | $13.64 |
| Food and Beverage | $200 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 1 companies. The companies reported $1,116,457 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company · Active, not recruiting · NCT06859268 - A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic alzheimer's disease
Eli Lilly and Company - Assessment of safety and efficacy of intravenous remternetug in early symptomatic alzheimers disease
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.